spacer
home > ebr > Summer 2016
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2016

   
Text
PDF
Editor’s Letter

EBR’s Editor Deborah O’Neil introduces July’s edition by highlighting the speed at which pharma is moving towards an age of biologics, while discussing the emerging possibility of earlier diagnosis for all patients.
 
view
download pdf
bullet
BioResearch and Innovation
Dementia Spotlight

How to Get a Pre-Competitive Edge


Rodrigo Barnes
at Aridhia discusses the possibility of unlocking the secrets of dementia to reduce its effect. With the costs of the disease – both economic and personal – on the rise, the time is right for a more collaborative approach to curing it.
 
view
download pdf
Liquid Biopsies

Translating Research into Reality: Part 1


As DNA sequencing looks increasingly towards the use of liquid biopsies, the industry moves ever-closer to developing personalised treatment for all patients. Paul Elvin at Aptus Clinical explains the need to target specific mutations, and the effect that new ctDNA analysis may have on patients and developers alike.
 
view
download pdf
BioDiscovery
Biomarkers and Diagnostics

The Secrets in our Cells


Diamond Light Source’s Mary Cruse
sheds light upon recent work undertaken in cancer research, and the prospect of tailoring treatment to the genetic codes of any given patient – stating that perhaps the successful cure lies in each individual’s chemistry.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
Comment: Shipment Conditions

How Strong is a Peptide Bond?


Have you ever wondered how much you could save on your logistics costs? According to Dr Henk J Bak at Eurosequence, there is a simple solution: bidding farewell to outdated methods and adopting more relevant shipping procedures.
 
view
download pdf
In Brief

Less is More


Governments, payers and patients alike are all calling for businesses worldwide to “do more with less”. Emile Bellott looks at the challenges we face as demands placed on the healthcare system threaten to intensify.
 
view
download pdf
bullet
BUSINESS STRATEGY
Content Management Software

Curse of the Patchwork Monster


The transformation of the life sciences landscape due to the digital revolution has created a stronger, quicker supply chain process. However, John Chinnici at Veeva Systems explains that despite its benefits, paper-based processes are still used by many companies. This can be combatted by implementing a fully digitalised supply chain.
 
view
download pdf

eHealth Revolution

From the Outside


Innovation from external sources has the potential to revolutionise the biopharma industry. Dr Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré andDr Richard Beetz at Arthur D. Little suggest that by embracing the digital, a positive change could be created for patient care, even if it means advances in other areas lose pace.

 
view
download pdf
bullet
RESEARCH AND DEVELOPMENT
Q&A: Idiopathic Pulmonary Fibrosis

Breathing Easy


In our latest Q&A, Dr Marilyn Glassberg enlightens EBR on everything from the main themes raised at ATS 2016 to her recent research, before revealing her biggest lesson in life.
 
view
download pdf
bullet
BIOIMAGING
Two-Photon Microscopy

The Next Step


A plethora of options have emerged to improve imaging capabilities for microscopists. Laser Quantum’s Andrew Wells explains the change in the priorities of manufacturers of laser equipment, and discusses the benefits of using ultra-fast lasers.
 
view
download pdf
bullet
CELL-BASED RESEARCH
Cell Disruption

Under Pressure


Technology that performs mechanical lysis and homogenisation of cells are often sold on the basis of the pressure they are able to reach. Recent research undertaken by Dr Matthew Lougher of Constant Systems, however, demonstrates that the success of mechanical cell disruptions depends on much more than pressure.
 
view
download pdf
Cell Culture Development

Up to Speed


Research shows that reducing the development time and costs associated with cell culture processes can be achieved by instigating high-throughput methods. Shahid Rameez and Abhinav A Shukla at KBI Biopharma discuss what this means for progress in novel biotherapeutics and their use in clinical trials.
 
view
download pdf
bullet
THERAPEUTIC DEVELOPMENT
Biosimilar Manufacturing

Gaining Ground


ProductLife Group’s Barbara Testa highlights the fact that the biosimilar sector is wrought with challenges regarding patient satisfaction and understanding – she explains that biosimilar popularity continues to rise, but physicians remain tentative.
 
view
download pdf
Genetic Disorder Therapeutics

Two Pillars of Fledgling RNA Medicine


It is becoming progressively difficult to find efficient, predictable and safe intracellular delivery strategies for curing genetic disorders. With the hope that a fuller understanding of RNA therapies will accelerate the process, Max Ryadnov at the National Physical Laboratory outlines the two main obstacles facing researchers and developers.
 
view
download pdf
Developments in Biosimilars

Winning the Race


The biosimilar testing process is complex, but it is becoming increasingly possible to employ a successful development programme. Dr Jon S Kauffman, Dr Weihong Wang and Dr Frederic Girard at Eurofins explore the feasibility of implementing these methods across the biopharma sector.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

POP TEST ADDRESSES THE PROBLEM OF UNRELIABLE DATA FROM CONTINUOUS GLUCOSE MONITORS

A major insight relating to the unreliability of data from continuous glucose monitors was published in the Nature journal, “Scientific Reports”, by Neil Theise, MD., the Lead Scientist of Pop Test, LLC and colleagues. The discovery of the “Interstitium”, a newfound human organ, by Dr. Theise and his collaborators, can be viewed by using the link https://www.nature.com/articles/s41598-018-23062-6 Continual glucose monitoring via an indwelling cutaneous needle measuring glucose in interstitial fluid (now identified to be in the “interstitium”) has been a game changer in the treatment of type 1 diabetes mellitus because of its accuracy. However, the needles used to collect this glucose containing fluid often fail in as little as a week. Despite the reliance on fluid from this space, the microanatomy of the interstitium has never been defined. The sensors currently in use were developed with the presumption of interstitial fluid being located somewhere in the sub-epidermal layers of the skin, but the actual anatomy relating to needle placement was always unclear.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement